Cambridge Enterprise announces three appointments to address demand for services in the ec...


17-04-2009

Cambridge Enterprise Limited, the University of Cambridge’s commercialisation office, is pleased to announce the appointments of Dr Gillian Davis, Technology Manager to the Physical Sciences Team, Dr Amanda Wooding, Technology Manager and Dr Steven Suchting, Technology Associate to the Life Sciences team.

All three will strengthen and complete the organisation's current complement of highly skilled technology transfer staff.

Innovation and knowledge transfer are seen as key factors in helping to reverse the economic downturn. The demand for Cambridge Enterprise’s services from internal and external customers and the University’s many research sponsors is at an all time high.

The three appointments bring a wealth of experience to Cambridge Enterprise’s team needed to fulfil the business plan approved by the University Finance Committee.

Dr Amanda Wooding was previously Director of Business Development with Acambis and her experience includes in and out technology licensing activities with both universities and companies. Dr Gillian Davis brings to Cambridge Enterprise extensive experience of research and development, as well as, business management in a wide range of hi-tech fields from liquid crystal displays and optical fiber communications to DSP software for noise reduction and microfluidics. Dr Steven Suchting had his own doctoral results commercialised by Cancer Research Technology while at the University of Oxford before four years postdoctoral studies at the Collège de France in Paris.

Cambridge Enterprise currently manages over 450 active agreements, 1100 individual patents representing 310 patent families and is adding approximately 45 new patents a year to its portfolio. Between them, the Life Science and Physical Science teams review over 120 new inventions annually and work closely with their inventors to determine the best commercialisation route.

Cambridge Enterprise, through its consultancy, technology transfer and seed funds teams, is well placed to respond to the ever increasing demand for the commercial dissemination of research results through consultancy, licensing agreements or company spin-outs which can provide both short, medium and and long term economic and societal benefits.

Cambridge Enterprise Limited, University of Cambridge

Cambridge Enterprise Limited is a wholly owned subsidiary of the University of Cambridge, responsible for the commercialisation of University intellectual property. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations. Cambridge Enterprise provides access to angel and early stage capital through the Cambridge Enterprise Seed Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring, specialist Surgeries and other related programmes.

The University leads the world in transformative research and Cambridge Enterprise is well placed to support the academics to find the best commercialisation route for their innovations either through licensing or company creation. In 2007/08 income from licensing, consultancy and equity transactions exceeded £10 million, of which £8 million represents distributions to University departments and academics.

Further information on Cambridge Enterprise can be found at: http://www.enterprise.cam.ac.uk 

*******

For further information please contact:
Shirley Jamieson
Head of Marketing
Cambridge Enterprise Limited
Tel: 01223 760 339
shirley.jamieson@enterprise.cam.ac.uk

 

Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.

Cambridge Enterprise, University of Cambridge